

To
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, MUMBAI – 400 001.

Date: 31-10-2022

Dear Sir / Madam,

Sub: Outcome of Board Meeting held on 31-10-2022

Unit: Hindustan Bio Sciences Limited (Scrip Code: 532041)

With reference to the subject cited, this is to inform the exchange that at the Board Meeting of Hindustan Bio Sciences Limited held on Monday, the 31st day of October, 2022 at 02.00 p.m. at the registered office of the company at Plot No.31, Sagar Society, Road No.2, Banjara Hills, Hyderabad-500034, Telangana, the following were considered and approved:

1. Un-audited financial results of the company for the quarter and half year ended 30th September, 2022 (enclosed as annexure)
2. Limited Review Report for the quarter and half year ended 30th September, 2022. (enclosed as annexure)

The meeting concluded at 3.10 P.M

Thanking you

Yours faithfully,

For **Hindustan Bio Sciences Limited**



J Varun Varma

Director

(DIN: 00515430)



HINDUSTAN BIO SCIENCES LIMITED
Plot No.31, Sagar Society, Road No.2, Banjara Hills, Hyderabad 500 034
Phone No. 23555161, Fax 40205171

STATEMENT OF UN AUDITED RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER,2022

(Rs. In lakhs)

Sl. No.	Particulars	Quarter ended			Half year ended		Year ended
		30.09.2022 (Unaudited)	30.06.2022 (Unaudited)	30.09.2021 (Unaudited)	30.09.2022 (unaudited)	30.09.2021 (unaudited)	31.03.2022 (Audited)
1	Income from Operations						
	(a) Revenue from operations	-	27.14	-	27.14	19.42	43.06
	(b) Other Income	-	-	5.24	-	5.24	-
	Total Revenue (1)	-	27.14	5.24	27.14	24.66	43.06
2	Expenses						
	(a) cost of material consumed	-	-	-	-	-	-
	(b) Purchases of Stock -in-trade	-	-	-	-	-	-
	(c) Changes in Inventories of finished goods, Stock - in-Trade and Work-in-Progress	-	18.29	-	18.29	13.03	23.69
	(d) Employee Benefit Expenses	-	-	-	-	-	-
	(e) Finance Costs	6.12	5.93	6.12	12.05	12.18	24.05
	(f) Selling Expenses	0.06	0.03	0.08	0.09	0.15	0.50
	(g) Depreciation and amortisation Expenses	-	0.33	-	0.33	0.23	0.61
	(h) Other Expenses	0.11	0.10	0.08	0.21	0.16	0.34
	Total Expenses(2)	1.20	4.97	4.49	6.17	11.98	45.32
3	Profit/(Loss) before Exceptional& Extraordinary items and tax (1 -2)	7.49	29.65	10.77	37.14	37.73	94.51
4	Exceptional items	(7.49)	(2.51)	(5.53)	(10.00)	(13.07)	(51.45)
5	Profit/(Loss) before tax(3 -4)	-	-	-	-	-	-
6	Tax Expenses	(7.49)	(2.51)	(5.53)	(10.00)	(13.07)	(51.45)
	(a) Current Tax	-	-	-	-	-	-
	(b) previous Taxes	-	-	-	-	-	-
	(b) Deferred Tax	-	-	0.03	-	0.03	0.03
7	Profit/(Loss) for the period from continuing operations(5-6)	(7.49)	(2.51)	(5.50)	(10.00)	(13.04)	0.34
8	Profit/(Loss) from discontinued operations	-	-	-	-	-	(51.76)
9	Tax Expense of discontinued operations	-	-	-	-	-	-
10	Profit /Loss from Discontinued operations after tax(8-9)	-	-	-	-	-	-
11	Profit/(Loss) for the period(7+10)	(7.49)	(2.51)	(5.50)	(10.00)	(13.04)	-
12	Other Comprehensive Income						(51.76)
	A (1) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(2) Income tax relating to items that will not be re- classified to profit or loss	-	-	-	-	-	-
	B (1) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(2) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
13	Total Comprehensive Income for the period (11+12) (comprising Profit (Loss) and other comprehensive income for the period	(7.49)	(2.51)	(5.50)	(10.00)	(13.04)	(51.76)
14	Paid up Equity Capital(Face value of Rs. 10/- each)	1,025.08	1,025.08	1,025.08	1,025.08	1,025.08	1,025.08
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year						
16	Earnings per equity share for continuing operations						(946.37)
	(A) Basic	(0.07)	(0.02)	(0.05)	(0.10)	(0.13)	(0.50)
	(B) Diluted	(0.07)	(0.02)	(0.05)	(0.10)	(0.13)	(0.50)
17	Earnings per equity share for discontinuing operations						
	(A) Basic	-	-	-	-	-	-
	(B) Diluted	-	-	-	-	-	-
18	Earnings per equity share(for discontinuing & continuing operations						
	(A) Basic	(0.07)	(0.02)	(0.05)	(0.10)	(0.13)	(0.50)
	(B) Diluted	(0.07)	(0.02)	(0.05)	(0.10)	(0.13)	(0.50)




HINDUSTAN BIO SCIENCES LIMITED
Plot No.31, Sagar Society, Road No.2, Banjara Hills, Hyderabad 500 034
Phone No. 23555161, Fax 40205171
STATEMENT OF ASSETS AND LIABILITIES


	PARTICULARS	As at	
		30.09.2022	31.03.2022
	ASSETS		
1	Non Current Assets		
	(a) Fixed Assets		
	Tangible Assets		
	(b) Deferred Tax Asset	3.77	3.98
	(c) Long Term Loans & Advances	0.56	0.56
	Total Non Current Assets	238.97	238.97
2	Current Assets	239.53	239.53
	(a) Stock in Trade	0	0
	(b) Trade Receivables	38.97	13.50
	(c) Cash and Cash Equivalents	0.87	0.91
	(d) Short Term Loans and Advances	32.81	39.66
	Total Current Assets	72.65	54.07
	TOTAL ASSETS	315.95	297.58
	EQUITY AND LIABILITIES		
1	Share Holders Funds		
	(a) Share Capital	1025.08	1025.08
	(b) Reserves and Surplus	(956.38)	(946.37)
	Total of Share Holders Funds	68.70	78.71
2	Non Current Liabilities		
	(a) Long Term Borrowings	115.72	107.17
	Total Non Current Liabilities	115.72	107.17
3	Current Liabilities		
	(a) Short Term Borrowings	128.94	109.48
	(b) Trade Payables		
	i. Total Outstanding dues of Micro Enterprises & Small Enterprises	0	0
	ii Total Outstanding dues of Creditors other than Micro Enterprises and small enterprises	0.24	0.12
	Other Current Liabilities	0	0
	Short Term Provisions	2.35	2.10
	Sub Total -Current Liabilities	131.53	111.70
	TOTAL EQUITY AND LAIBILITIES	315.95	297.58

Notes:

- 1 The Un Audited Financial Results were taken on record by the Board of Directors in their meeting held on 31.10.2022
- 2 Previous Year figures have been regrouped wherever necessary.

Place Hyderabad
Date 31.10.2022

Hindustan Bio Sciences Limited

J. Varun Varma
Director
(DIN:00515430)



HINDUSTAN BIO SCIENCES LIMITED

Cash Flow Statement for the period ended 30th Sept.2022 (Rs. In lakhs)


Particulars	30th Sept. 2022	31st March 2022
A CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit/(Loss) Before Tax		
Adjustments for:	(10.00)	(51.45)
Provision for Debtors	-	22.70
Depreciation	0.21	0.34
Operating Profit before Working Capital Changes	(9.79)	(28.41)
Movements in Working Capital		
Increase/(Decrease) in Trade Payables	0.11	(28.99)
Decrease/(Increase) in Provisions	0.25	(1.07)
Increase/(Decrease) in Borrowings	19.46	(3.10)
Increase/(Decrease) in Trade Receivables	(25.47)	25.53
Increase/(Decrease) in Inventories		-
Decrease/(Increase) in Other financial assets		-
Decrease/(Increase) in Other current assets	6.85	1.73
Cash generated from operations	(8.59)	(34.31)
Less: Income Tax Refund/paid	-	0.03
Net Cash flow from Operating activities	(8.59)	(34.28)
B CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Fixed Assets	-	(0.35)
Net Cash used in Investing activities	-	(0.35)
C CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from Long term Borrowings	8.55	33.87
Interest paid		
Net Cash used in financing activities	8.55	33.87
Net increase in cash & Cash Equivalents	(0.04)	(0.76)
Cash and Cash equivalents at the beginning of the year	0.91	1.67
Cash and Cash equivalents at the end of the year	0.87	0.91


The above Cash Flow statement has been prepared using the Indirect Method as set out in Accounting Standard 3 on Cash Flow Statement.

Place Hyderabad
Date 31.10.2022

Hindustan Bio Sciences Limited

J.Varun Varma
Director
(DIN: 00515430)





VASG & ASSOCIATES
Chartered Accountants

503/A, 5th Floor, Kubera Towers,
Narayanaguda, Hyderabad - 500 029
Ph : 040-66849660 / 66867732
E-mail : info@vasg-ca.com
vasgassociates@gmail.com

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE
FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF
M/S HINDUSTAN BIO SCIENCES LIMITED**

We have reviewed the accompanying statement of unaudited financial results of M/S. HINDUSTAN BIO SCIENCES LIMITED (the "Company"), for the quarter and period ended September 30, 2022, being prepared by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 as amended.

The preparation of this statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('IND AS 34'), prescribed under section 133 of the companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India is the responsibility of the company's management and has been approved by the Board of Directors of the company. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date : 31-10-2022
Place : Hyderabad

For VASG & ASSOCIATES
Chartered Accounts
Firm Reg.No:060705

hshana

A VISWANATHA RAO
Partner
M No:029597

UDIN : 22029597BBMKNK8926

